Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma

This study is trying to identify the right dose of a long-acting medicine called WIN378 for people with moderate or severe asthma. WIN378 blocks the action of a protein called TSLP which causes inflammation in the lung and may contribute to your asthma control and symptoms. The study will test how doses of WIN378 are handled by your body (pharmacokinetics) and assess the safety of the medicine and will assess markers of asthma inflammation in your breath and in your blood, lung function and asthma control (pharmacodynamics).

NCT Number	NCT07120503
Lead Sponsor	Windward Bio
Conditions	Asthma (Diagnosis)
Enrollment	136 participants
Start Date	2025-07-24
Primary Completion	2027-07 (estimated)
Study Completion	2027-10 (estimated)
Updated on ClinicalTrials.gov	2026-04-07